Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–67 of 67 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo po TID Clear all
Completed Not applicable Interventional Results available

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

NCT00945334
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Neomycin, Placebo, Rifaximin
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 7, 2026, 1:13 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

NCT00650754
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Unexplained Infertility
Interventions
Dehydroepiandrosterone, Placebo
Dietary Supplement · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 37 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Pentoxifylline on PAI-1 in an Obese Population

NCT00770328
View directory record Official record
Conditions
Obesity
Interventions
Pentoxifylline, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

NCT00983580
View directory record Official record
Conditions
Adenomatous Polyp
Interventions
Aspirin, Eflornithine, Laboratory Biomarker Analysis, Placebo, Telephone-Based Intervention
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 7, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors

NCT06028022
View directory record Official record
Conditions
Estrogen Receptor-Positive Breast Carcinoma
Interventions
Mushroom Extract, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Dietary Supplement · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Albert Lea, Minnesota • Baxter, Minnesota • Bemidji, Minnesota + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 7, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.

NCT06253117
View directory record Official record
Conditions
Recurrent Acute Pancreatitis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 4 Interventional Results available

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

NCT00452543
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
Interventions
acamprosate, escitalopram, Medical management, Placebo
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 7, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

NCT06731894
View directory record Official record
Conditions
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Interventions
Biospecimen Collection, Cannabidiol, Dronabinol, Placebo Administration, Survey Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

NCT01489813
View directory record Official record
Conditions
Bladder Cancer
Interventions
Genistein, Sugar pill
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Chronic Obstructive Pulmonary Disease

NCT00104637
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions
sildenafil citrate, Placebo
Drug
Lead sponsor
Kawut, Steven, MD
Individual
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 7, 2026, 1:13 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex

NCT00956150
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Lactulose Breath Test, Rifaximin, Placebo
Procedure · Drug
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 7, 2026, 1:13 AM EDT
Terminated Phase 2 Interventional Results available

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT02569437
View directory record Official record
Conditions
Polyp of Nasal Sinus
Interventions
Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

NCT04705415
View directory record Official record
Conditions
Healthy
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth

NCT00617240
View directory record Official record
Conditions
Weight Gain
Interventions
metformin, placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 3 Interventional Results available

A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT05206370
View directory record Official record
Conditions
Smoking Cessation
Interventions
Cytisinicline, Placebo, Behavioral support
Drug · Behavioral
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
DeLand, Florida • Fort Myers, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 7, 2026, 1:13 AM EDT
Withdrawn Phase 2 Interventional

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

NCT04713202
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
Interventions
Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo
Drug · Other
Lead sponsor
Chandrikha Chandrasekhara
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 7, 2026, 1:13 AM EDT
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

NCT04988035
View directory record Official record
Conditions
COVID-19
Interventions
Danicopan, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 7, 2026, 1:13 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

NCT04810091
View directory record Official record
Conditions
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Interventions
Placebo Administration, Questionnaire Administration, Telotristat Ethyl
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 7, 2026, 1:13 AM EDT
Recruiting Phase 2 Interventional

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer

NCT06855524
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Breast Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Oligo-fucoidan, Placebo Administration, Questionnaire Administration
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 1:13 AM EDT